Prevalence of mental disorders in Europe: Results from the European study of the epidemiology of mental disorders (ESEMeD) project, Acta Psychiatrica Scandinavica. Supplementum, issue.420, pp.8-20, 2004. ,
, Practice guideline for the assessment and treatment of patients with suicidal behaviors, American Psychiatric Association, vol.160, pp.1-60, 2003.
, Practice guideline for the treatment of patients with major depressive disorder, American Psychiatric Association, pp.1-152, 2010.
Antidepressants and hepatotoxicity: A cohort study among 5 million individuals registered in the French national health insurance database, CNS Drugs, vol.32, pp.673-684, 2002. ,
Psychiatric medications: Adverse cutaneous drug reactions, Clinics in Dermatology, vol.31, pp.101-109, 2013. ,
Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development, Nature Reviews Drug Discovery, vol.9, pp.628-642, 2010. ,
Cross-national epidemiology of DSM-IV major depressive episode, BMC Medicine, vol.9, p.90, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00617550
Risks of all-cause and suicide mortality in mental disorders: A meta-review, World Psychiatry, vol.13, pp.153-160, 2014. ,
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis, Lancet, vol.391, pp.1357-1366, 2018. ,
Major depressive disorder treatment guidelines in America and Europe, Journal of Clinical Psychiatry, vol.71, p.4, 2010. ,
Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature, Psychological Medicine, vol.43, pp.471-481, 2013. ,
Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties, British Journal of Pharmacology, vol.171, pp.3604-3619, 2014. ,
ECDEU assessment manual for psychopharmacology. Rockville MD: US Department of Health, Education and Welfare publication ADM 76-338, 1976. ,
Guidelines for good pharmacoepidemiology practices (GPP), Pharmacoepidemiology and Drug Safety, vol.17, pp.200-208, 2008. ,
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, European Neuropsychopharmacology, vol.16, issue.2, pp.93-100, 2006. ,
Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness, CNS Drugs, vol.24, pp.479-499, 2010. ,
Summary of product characteristics: Valdoxan, Lancet, vol.367, pp.2041-2043, 2006. ,
Dermatologic side effects of psychotropic medications, Psychosomatics, vol.55, pp.1-20, 2014. ,
Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale, Journal of Psychopharmacology, vol.29, pp.1119-1128, 2015. ,
Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale, Journal of Psychopharmacology, vol.24, pp.111-120, 2010. ,
Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study, International Clinical Psychopharmacology, vol.19, pp.271-280, 2004. ,
Suicide and antidepressants: What current evidence indicates, Mens Sana Monographs, vol.10, pp.33-44, 2012. ,
Characterisation of agomelatine-induced increase in liver Enzymes: Frequency and risk factors determined from a pooled analysis of 7605 treated patients, CNS Drugs, vol.30, pp.877-888, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01373303
Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: A cohort and nested case-control study using automated health data sources, CNS Drugs, vol.33, pp.383-395, 2019. ,
Using second-generation antidepressants to treat depressive disorders: A clinical practice guideline from the American college of physicians, Annals of Internal Medicine, vol.149, pp.725-733, 2008. ,
International ethical guidelines for epidemiological studies: by the Council for International Organizations of Medical Sciences (CIOMS), American Journal of Epidemiology, vol.170, issue.11, pp.1451-1452, 2009. ,
The measurement of disability, International Clinical Psychopharmacology, vol.11, pp.89-95, 1996. ,
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies, BMJ, vol.348, 1888. ,
Antidepressant-induced liver injury: A review for clinicians, American Journal of Psychiatry, vol.171, pp.404-415, 2014. ,
Liver function test abnormalities in depressed patients treated with antidepressants: A real-world systematic observational study in psychiatric settings, PLoS One, p.155234, 2016. ,
Escitalopram in the longterm treatment of major depressive disorder, American Journal of Psychiatry, vol.18, pp.83-89, 2006. ,
The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study, Hum Psychopharmacol Clin Exp, 2020. ,
URL : https://hal.archives-ouvertes.fr/inserm-02969124
,
,